Voyager updates on Alzheimer’s programs ‘compelling,’ says H.C. Wainwright

H.C. Wainwright argues that Voyager’s presentations at the Alzheimer’s & Parkinson’s Disease meeting April 1-5 “further strengthen the case” for its dual approach to tau-targeted therapy in Alzheimer’s with “compelling” new preclinical data from both the anti-tau antibody VY7523 and tau silencing gene therapy VY1706. The firm, which reiterates a Buy rating and $30 price target on the shares, believes upcoming catalysts, including tau PET data from the VY7523 multiple ascending dose study in the second half of 2026 and an investigational new drug filing for VY1706 in 2026, can “unlock significant value for shareholders.”